drugset / Trial / NCT06770504
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Phase 1
Not yet recruiting
7 enrolled
Institute of Hematology & Blood Diseases Hospital, China
China Immunotech (Beijing) Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 START T-cell therapy in patients with autoimmune hemolytic anemia who have failed ≥3 lines of therapy.
Timeline
- Start
- 2025-01-16
- Primary completion
- 2025-12-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YTS109 | Cell therapy | 500000 cells/kg | — |
| Subject | YTS109 | Cell therapy | 1e+06 cells/kg | — |